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Objective: To investigate the azole susceptibility of Candida albicans (C. albicans)
from vulvovaginal candidosis patients and to analyze the relationship between ERG11
gene mutations in these isolates and azole resistance.
Methods: Three hundred and two clinical isolates of Candida species were collected.
Azole susceptibility was tested in vitro in microdilution studies. The ERG11 genes of 17
isolates of C. albicans (2 susceptibles, 5 dose-dependent resistants and 10 resistants) were
ampliﬁed and sequenced.
Results: Of the 302 isolates collected, 70.2% were C. albicans, of which 8.5%, 3.8% and
4.2% were resistant to ﬂuconazole, itraconazole and voriconazole, respectively. In total,
27 missense mutations were detected in ERG11 genes from resistant/susceptible dose-
dependent isolates. Among them, Y132H, A114S, and Y257H substitutions were most
prevalent and were known to cause ﬂuconazole resistance. G464S and F72S also have
been proved to cause ﬂuconazole resistance. Two novel substitutions (T285A, S457P) in
hotspot regions were identiﬁed.
Conclusions: Twenty seven mutations in the ERG11 gene were identiﬁed in azole-
resistant C. albicans isolates, which indicated a possible relation with the increase in
resistance to azole drugs and the recurrence of vulvovaginal candidosis. The relationship
of two novel substitutions (T285A, S457P) with ﬂuconazole resistance needs to be further
veriﬁed by site-directed mutagenesis.1. Introduction
Vulvovaginal candidiasis (VVC) is one of the most frequent
ailments in the ﬁelds of obstetrics and gynecology and resultsfrom over-abundant growth of Candida species in the vaginal
mucosa. It has been estimated that approximately 75% of all
women will experience at least one episode of VVC during their
lifetime, among which 40%–50% will experience a further
episode [1]. Moreover, 5%–8% of adult women have
symptomatic recurrent VVC (RVVC), which is deﬁned as  4
episodes per year [2]. Patients generally suffer from various
symptoms, including burning, itching, soreness, abnormal
vaginal discharge and pain during sexual intercourse [3].
Candida albicans (C. albicans) is the predominant species
causing vaginitis and accounts for most VVC cases, followed
by Candida glabrata (C. glabrata), Candida tropicalis
(C. tropicalis), Candida krusei (C. krusei) and Candida
parapsilosis (C. parapsilosis) [4].an open access article under the CC BY-NC-ND
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resistance to azole antifungal agents in C. albicans strains,
including (i) alteration of the target enzyme, which is encoded
by the ERG11 gene. In C. albicans, the target enzyme of azoles
is 14-demethylase (Erg11p), a key enzyme in the ergosterol
synthesis pathway. Azoles block fungal membrane formation [5].
Mutations in Erg11p can decrease the afﬁnity of the target
enzyme for azoles [6,7]. (ii) ERG11 overexpression also
contributes to antifungal resistance. Previous studies have
shown that mutations in some transcriptional activators such
as upc2p may upregulate ERG11 [8,9]. (iii) Antifungal
resistance may result from decreased intracellular drug
accumulation following the upregulation of 2 drug efﬂux
pumps, which are encoded by the ATP-binding cassette trans-
porter genes CDR1, CDR2 and MDR1 [10,11]. (iv) Bioﬁlm
formation may also cause resistance to antifungal drugs [12].
The purpose of the present study was to investigate the
species distribution and to identify mutations in the C. albicans
ERG11 gene associated with azole resistance in women with
VVC in Changchun, China.
2. Materials and methods
2.1. Media, drugs and agents
Modiﬁed Sabouraud dextrose agar contained 20 g/L
dextrose, 10 g/L peptone, 20 g/L agar and 50 mg/L chloromy-
cetin. CHROMagar was prepared as recommended by the
manufacturer. Roswell Park Memorial Institute (RPMI) 1640
broth was prepared by dissolving 10.4 g/L RPMI 1640 powder
(with glutamine, but without NaHCO3) and 34.53 g/L 3-(N-
morpholino)-propanesulfonic acid in water, adjusting the pH to
6.9–7.0 and sterilizing the solution by ﬁltration. RPMI 1640 agar
medium was prepared by dissolving 2% dextrose and 1.5% agar
in RPMI 1640 broth. Standard powders of ﬂuconazole, itraco-
nazole and voriconazole (Sigma, Chemical Co., St Louis, MO,
USA) were used.
2.2. Isolate collection and identiﬁcation
Clinical Candida samples (n = 302) were collected from
patients with VVC in the Second Clinical Hospital of Jilin
University during February to October of 2013. All study par-
ticipants provided informed consent and the study design was
approved by the Ethical Committee of Institute of Zoonosis, Jilin
University, China. Among these isolates, 210 (69.5%) were
obtained from patients with sporadic or infrequent episodes of
vaginitis, a condition commonly referred to as acute VVC
(AVVC) (Group 1). In addition, 92 isolates (30.5%) were from
patients with RVVC episodes (Group 2). The identity of all
isolates was conﬁrmed at the species level using CHROMagar
Candida (CHROMagar; Paris, France) and the API 20C AUX
yeast identiﬁcation kit (bioMe´rieux SA, Marcy l'E toile, France).
2.3. Drug susceptibility testing
As recommended in the Clinical Laboratory Standards
Institute M27-A3 reference document [13], C. albicans
susceptibility and resistance to ﬂuconazole, itraconazole, and
voriconazole were measured using the M27-A3 broth dilutionmethod. The ATCC 6258 and ATCC 22019 strains were used as
controls.
Strains showing minimum inhibitory concentrations (MICs)
of  8 mg/mL,  0.125 mg/mL and  1 mg/mL with ﬂuconazole,
itraconazole, and voriconazole, respectively were considered as
susceptible (S). Strains with MIC values of  64 mg/mL,
 2 mg/mL and  4 mg/mL with ﬂuconazole, itraconazole and
voriconazole, respectively were considered as resistant (R).
Strains showing MIC values of 16–32 mg/mL, 0.25–0.5 mg/mL
and 1–4 mg/mL with ﬂuconazole, itraconazole and voriconazole,
respectively were considered to have sensitivity that was dose-
dependent (SDD).
2.4. DNA extraction
Total genomic DNA from each resistant C. albicans isolate
and 2 randomly selected susceptible isolates were extracted
using the yeast DNA kit (Tiangen, China), according to the
manufacturer's instructions. DNA concentrations were measured
with a GeneQuant spectrophotometer (Amersham Biosciences,
USA).
2.5. PCR ampliﬁcation and sequencing of the ERG11
gene
ERG11 genes from 17 isolates were ampliﬁed by PCR using
primers with the following sequences: ERG11-F:50-CAAGAA-
GATCATAACTCAAT-30and ERG11-R:50-AGAACACTGAA
TCGAAAG-30. PCR reactions were performed in a 25 mL
mixture containing 2.5 mL of 10 × PCR buffer (with Mg2+), 2 mL
of genomic DNA, 10 ng of each deoxynucleotide triphosphates,
1 mL of each primer (10 mmol/L) and 0.25 mL Taq DNA
polymerase (1 IU/mL). PCR was performed using the following
thermocycling conditions: denaturation at 94 C for 5 min; 35
cycles of denaturation (94 C, 30 s), annealing (53 C, 30 s) and
extension (72 C, 2 min) and one ﬁnal extension cycle at 72 C
for 10 min. The size of each PCR product (1641 bp) was
analyzed preliminarily by electrophoresis in 0.8% agarose gels
and visualized under an ultraviolet spotlight, after staining with
ethidium bromide. PCR fragments of the 17 C. albicans isolates
were puriﬁed with the BioDev DNA puriﬁed kit (China) and
sequenced with an automated DNA sequencer ABI prism 3700
DNAMAN analyzer (Applied Biosystems) using standard pro-
tocols and previously designed primers [14]. For each strain, the
entire ERG11 open reading frame sequence was compared
with a previously described ERG11 sequence (accession
number X13296) obtained from a ﬂuconazole-susceptible
strain [15].
2.6. Statistical analysis
Chi-square (c2) test was used for statistical analysis with
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was
used to assign statistical signiﬁcance.
2.7. Nucleotide sequence accession numbers
The ERG11 gene sequences of 17 C. albicans clinical iso-
lates determined in this study were deposited in the GenBank
database under accession numbers KM609916–KM609932.
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3.1. Species identiﬁcation
In total, 302 Candida isolates were collected from non-
pregnant outpatients (aged 21–49 years) suspected of having
VVC. Among these, 212 C. albicans, 28 C. glabrata, 22Table 1
Distribution of Candida species among patients with AVVC and RVVC.
n (%).
Species AVVC RVVC Total
C. albicans 159 (75.7) 53 (57.6) 212 (70.2)
C. glabrata 18 (8.6) 10 (10.9) 28 (9.3)
C. tropicalis 14 (6.7) 8 (8.7) 22 (7.3)
C. krusei 8 (3.8) 6 (6.5) 14 (4.6)
C. parapsilosis 5 (2.4) 8 (8.7) 13 (4.3)
Other Candida spp. 6 (2.9) 7 (7.6) 13 (4.3)
Table 2
Antifungal susceptibility of vaginal C. albicans isolates.
Antifungal agent AVVC RVVC Total
R SDD S R SDD S R SDD S
Fluconazole 10 6 143 8 6 39 18 12 182
Itraconazole 3 2 154 5 2 46 8 4 200
Voriconazole 3 1 155 6 3 44 9 4 199
S, SDD, and R were deﬁned as a MIC value of  8, 16–32, or  64 mg/
mL of ﬂuconazole for C. albicans. S, SDD, and R were deﬁned as a MIC
value of  0.125, 0.25–0.5, or  1 mg/mL of itraconazole for
C. albicans. S, SDD, and R were deﬁned as a MIC value of  1, 1–4, or
 4 mg/mL of voriconazole for C. albicans.
Table 3
Results of in vitro antifungal susceptibility testing and ERG11 sequence ana
Isolates No. (GenBank No.) MIC (mg/mL) Misse
Type FLZ ITZ VOR
CHC114 (KM609920) AVVC > 64 0.031 3 0.50 C488T
CHC117 (KM609921) RVVC > 64 4.000 0 0.50 T495A
G154
CHC119 (KM609922) RVVC > 64 0.031 3 0.50 C515T
CHC122 (KM609924) RVVC > 64 8.000 0 4.00 G487
A171
CHC125 (KM609925) RVVC > 64 0.031 3 8.00 C515T
G109
CHC128 (KM609927) AVVC > 64 0.031 3 0.50 G487
CHC130 (KM609928) AVVC > 64 0.500 0 0.50 G487
CHC134 (KM609929) RVVC > 64 0.500 0 8.00 A217
T495A
A926
CHC157 (KM609930) RVVC > 64 0.031 3 4.00 G487
CHC160 (KM609931) RVVC > 64 8.000 0 8.00 T495A
G154
CHC95 (KM609917) RVVC 16 0.500 0 0.25 T541C
T1516
CHC106 (KM609918) RVVC 16 0.031 3 0.50 T848G
CHC120 (KM609923) AVVC 32 0.031 3 0.50 A650
CHC126 (KM609926) AVVC 32 0.500 0 1.00 A945
CHC169 (KM609932) AVVC 32 0.125 0 1.00 A945
CHC34 (KM609916) AVVC 8 0.250 0 0.50 A101
CHC108 (KM609919) AVVC 8 0.031 3 0.50 –
The newly observed substitutions were shown in bold. The sequence of C
X13296. FLZ: Fluconazole; ITZ: Itraconazole; VOR: Voriconazole.C. tropicalis, 14 C. krusei, and 13 C. parapsilosis isolates in
addition to 13 Candida spp. were identiﬁed. In total, 75% of
women (159/212) positive for C. albicans had AVVC, whereas
the remaining 25% (53/212) had RVVC. The distribution of the
isolates identiﬁed was shown in Table 1. There were 51 strains
of non-C. albicans spp. found among the 210 strains of AVVC
group (24.3%) and 39 strains of non-C. albicans spp. among the
92 strains of RVVC group (42.4%). The ratio of non-C. albicans
in the RVVC group was signiﬁcantly higher than that in the
AVVC group (P < 0.05).
3.2. Antifungal susceptibility tests
The results of in vitro susceptibility testing for the 212
clinical isolates of C. albicans were shown in Table 2. Ac-
cording to the Clinical and Laboratory Standards Institute deﬁ-
nitions, 30 isolates (14.2%) had reduced susceptibility to
ﬂuconazole (18 R and 12 SDD), 12 (5.7%) isolates had reduced
susceptibility to itraconazole (8 R and 4 SDD) and 13 isolates
(6.1%) had reduced susceptibility to voriconazole (9 R and 4
SDD). A signiﬁcantly higher percentage of isolates had reduced
susceptibility to ﬂuconazole than to itraconazole or voriconazole
(P < 0.05).
Among isolates identiﬁed in the AVVC outpatient group, 16/
159 (10.1%) had reduced susceptibility to ﬂuconazole (10 R and
6 SDD), 5 (3.1%) isolates had reduced susceptibility to itraco-
nazole (3 R and 2 SDD) and 4 isolates (2.5%) had reduced
susceptibility to voriconazole (3 R and 1 SDD). However, in the
RVVC group, 14/53 (26.4%) had reduced susceptibility to ﬂu-
conazole (8 R and 6 SDD), 7 (13.2%) isolates had reduced
susceptibility to itraconazole (5 R and 2 SDD) and 9 isolates
(17.0%) had reduced susceptibility to voriconazole (6 R and 3
SDD). The percentage of isolates with reduced susceptibility tolysis for 17 clinical isolates of C. albicans.
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. albicans isolates was compared with that of GenBank accession No.
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the AVVC group (P < 0.05), but no signiﬁcant differences were
found between the two groups in terms of itraconazole and
voriconazole susceptibility (P > 0.05).
3.3. Cross resistance among different isolates
Two isolates (CHC122 and CHC160) were resistant to all 3
types of azole antifungal agents; 5 isolates (CHC95, CHC117,
CHC125, CHC134 and CHC157) were resistant to 2 azoles and
8 isolates (CHC106, CHC114, CHC119, CHC120, CHC126,
CHC128, CHC130 and CHC169) were resistant to ﬂuconazole
alone (Table 3).
3.4. Mutations in the ERG11 gene
The size of the ERG11 coding region ampliﬁed by PCR was
1 640 bp. By analyzing ERG11 sequencing results from 17
C. albicans isolates, we found 62 mutations, of which 34 were
silent mutations that did not result in amino acid changes (data
not shown). Twenty-seven missense mutations were detected in
R/SDD isolates and 1 mutation was detected in 1 S isolate
(CHC34).
Among the 27 missense mutations identiﬁed in R/SDD iso-
lates, 15 mutations identiﬁed (A114S, A114V, Y257H, K128T,
G465S, F72S, D116E, Y132H, E266D, V437I, G464S, T123I,
N440S, R523G and V488I) have been reported previously and
12 were novel (S24G, K90R, N168S, V234G, N237D, E260G,
T285A, A317T, I333T, K344E, S457P, E517V) (Table 3).
Among them, T285A and S457P mutations were occurred in
hotspot regions.
4. Discussion
Among the isolates studied, nearly two-thirds (210/302) were
from AVVC patients and the others were from RVVC patients.
The most common species found among the isolates tested was
C. albicans (70.2% of all isolates), followed by C. glabrata
(9.3%) and C. tropicalis (7.3%). The species distribution of
Candida isolates was similar to a report in the US and a recent
report in Southern China [16,17].
There are limited data regarding the antifungal susceptibility
of yeast species causing VVC. In this study, the resistance rate
of C. albicans to ﬂuconazole in AVVC was 6.2% (10/159),
which is signiﬁcantly higher than the rate in Southern China [17],
which indicates differences in the genotype of the circulating
isolates or in the frequency of the use of ﬂuconazole between
different regions of China. However, the resistance rate of
C. albicans to itraconazole was 1.9% (3/159), which is similar
to that in Southern China (1.1%). The level of ﬂuconazole
resistance found in this study was signiﬁcantly higher than
that of itraconazole or voriconazole, possibly because
ﬂuconazole is more frequently used than itraconazole or
voriconazole. It is known that the activity of ﬂuconazole is
weaker than itraconazole and itraconazole is weaker than
voriconazole [18]. Therefore resistances against ﬂuconazole are
more frequently observed than itraconazole and voriconazole.
The ﬂuconazole resistance rate in the RVVC group was
signiﬁcantly higher than that in the AVVC group, which in-
dicates that more frequent use of ﬂuconazole can generate
resistance. In contrast, itraconazole and voriconazole are seldomused and the associated resistance rates between the AVVC and
RVVC groups are not signiﬁcant.
In the present study, the Y132H substitution was found in 5
isolates (CHC95, CHC117, CHC119, CHC125 and CHC160)
and G465S substitutions also occurred in two of the isolates
(CHC117, CHC160). The Y132H mutation is situated in the B–
B0 helix cluster, a highly conserved region among lanosterol
14a-demethylases that facilitates substrate binding. Mutations in
the B–B0 helix cluster can cause 4-fold increases in ﬂuconazole
MIC because of decreased afﬁnity between the target enzyme
and ﬂuconazole [5,19–21].
A high frequency of the D116E mutation was also found in
ﬂuconazole-resistant isolates (CHC117, CHC134 and CHC160),
which is consistent with the ﬁndings of Cernicka and Subik, who
identiﬁed D116E amino acid alterations in Erg11p that are
conserved in ﬂuconazole-resistant strains [22].
Combined A114S and Y257H substitutions were found in 4
isolates (CHC122, CHC128, CHC130 and CHC157); these
mutations were previously reported to occur simultaneously in
ﬂuconazole-resistant isolates [23]. A114S is located near to the
substrate channel in Erg11p, and its mutation may interfere
with the entry of inhibitor or binding to the active site [23].
Fluconazole MIC values were previously found to be 2- to 4-
fold greater in C. albicans with the Y257H mutation [24]. We
found that the combined A114S and Y257H substitutions were
associated with an 8-fold increase in ﬂuconazole resistance.
Y257H is located in the G helix, far away from the active center
or substrate access channel of the protein and thus does not
directly affect the afﬁnity of the Erg11 protein for azoles [25].
The contribution of the Y257H mutation to azole resistance
must be further veriﬁed by site-directed mutagenesis.
The G464S substitution only occurred in a single isolate
(CHC134), which was resistant to ﬂuconazole, itraconazole and
voriconazole. The G464S substitution occurs in the heme-
binding region and prevents the heme region amino acids from
binding to ﬂuconazole [26]. Previously, it was found that the
G464S substitution caused a 64-fold increase in the
ﬂuconazole MIC. Sanglard et al. also demonstrated that
Y132H and G464S could increase the resistance to
ﬂuconazole and itraconazole [27].
The F72S substitution was found in one azole-resistant strain
(CHC134). Changing the amino acid from a polar residue
(phenylalanine) to an apolar, neutral residue (serine) alters the
hydrophobic channel in terms of substrate access and the F72S
substitution prevents the substrate from accessing the active site,
resulting in azole resistance [26].
The V488I substitutions were found in one azole-resistant
strain (CHC95), combined with Y132H and E266D. Cernicka
and Subik also reported the same substitution in ﬂuconazole-
resistant strains [22]. The E266D substitution was detected in 3
azole antifungal SDD strains (CHC95, CHC126 and
CHC169). E266D probably does not contribute to azole
resistance because it is found in both azole-resistant and azole-
susceptible strains [5,27,28]. T123I substitution was found in
two resistant isolates (CHC119 and CHC125) and it was also
observed in two resistant isolates (C97 and C112) from Anhui
in China [29]. The location of this substitution in hot pot I
highlights the possible relationship with ﬂuconazole-resistance
and should be veriﬁed in future. The N440S substitution
found in SDD stain CHC95 was also found in a ﬂuconazole-
resistant clinical isolate CA490 [30]. The location of this
substitution in hot pot III indicates that they may play a role
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in two resistant isolates (CHC122, CHC160) and the substitution
has been identiﬁed in a ﬂuconazole-resistant clinical isolate
CA490, but the contribution of it to ﬂuconazole-resistant needs
further conﬁrmation [30]. V437I substitutions occurred in one
SDD isolate (CHC106), accompanied by other point
mutations. Some studies have reported the occurrence of the
V437I mutations in both azole-susceptible and azole-resistant
isolates [12,26,28]. The A114V substitution was found in one
ﬂuconazole-resistant strain (CHC114). The mutation occurs
near to the substrate channel in Erg11p and may interfere with
the entry of inhibitor or binding to the active site. The sub-
stitutions of T285A and S457P were the ﬁrst reported in this
study and their contribution to azole resistance must be further
veriﬁed by site-directed mutagenesis.
There are 38 missense mutations occurred in 9 R/SDD iso-
lates from RVVC patients. But only 8 missense mutations were
found in 6 R/SDD isolates from AVVC patients (Table 3). The
much higher mutation rate in the RVVC group than in the
AVVC group may indicate multiple nucleotide substitutions in
the ERG11 gene fragments that would increase ﬂuconazole
resistance and lead to the recurrence of VVC.
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